NCT00784927View on ClinicalTrials.gov

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2013

Study Completion Date

February 29, 2016

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

DRUG

cyclophosphamide

DRUG

dexamethasone

DRUG

lenalidomide

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259-5499

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00784927 - Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter